VivoSim Labs Announces Its NAMkind Liver, Intestine Models Validated For Predicting Toxicity, Side Effect Profiles Of Antibody Drug Conjugates

VivoSim Labs, Inc. (Nasdaq: VIVS) announced at the Society of Toxicology meeting that its NAMkind liver and intestine models have been validated for predicting toxicity and side effect profiles of antibody drug conjugates (ADCs). This validation is significant given the hundreds of ADCs in development and the potential for off-target toxicity in oncology applications. The NAMkind models are expected to enhance the selection and improvement of ADC candidates in drug development.